
Omeros Updates Zaltenibart Phase 3 PNH Trial
Omeros Updates Zaltenibart Phase 3 PNH Trial Omeros Corporation (Nasdaq: OMER) has announced significant progress in its Phase 3 clinical trial program for zaltenibart (OMS906), an investigational inhibitor of MASP-3,…












